CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma.
  
  LEARNING OBJECTIVES

  • Understand the biologic rationale for the use of chimeric antigen receptor (CAR) T-cell therapy directed at B-cell maturation antigen (BCMA) as a targeted therapeutic strategy for multiple myeloma (MM).
  • Appreciate the recent FDA approval of the BCMA-directed CAR T-cell therapy idecabtagene vicleucel for relapsed/refractory (R/R) MM, and identify patients for whom treatment with this novel agent should be considered.
  • Recall available efficacy and safety data with other CAR T-cell therapies directed at BCMA, and identify patients with R/R MM for whom participation in studies evaluating these strategies would be appropriate.
  • Recognize adverse events associated with approved and investigational CAR T-cell therapies directed at BCMA, and appropriately counsel patients with MM considering such treatment about the risks.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Jesús G Berdeja, MD
  Director of Multiple Myeloma Research
  Sarah Cannon Research Institute
  Tennessee Oncology
  Sarah Cannon Center for Blood Cancer
  Nashville, Tennessee
  
  Consulting Agreements: bluebird bio, Bristol-Myers Squibb Company, Celgene Corporation, CRISPR Therapeutics, Janssen Biotech Inc, Kite, A Gilead Company, Legend Biotech, Secura Bio, Takeda Oncology; Contracted Research: AbbVie Inc, Amgen Inc, Astex Pharmaceuticals, bluebird bio, Bristol-Myers Squibb Company, Celator Pharmaceuticals Inc, Celgene Corporation, Celularity, CRISPR Therapeutics, Curis Inc, EMD Serono Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, Ichnos Sciences, Incyte Corporation, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Kesios Therapeutics Ltd, Lilly, Novartis, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Poseida Therapeutics, Sanofi Genzyme, Takeda Oncology, Vivolux.
  
  EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Bristol-Myers Squibb Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.
  
  Release date: August 2021
  Expiration date: August 2022